Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasm Metastasis 7Stomach Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Lung Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

X-Rays 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Phantoms, Imaging 6Biopsy 5Nuclear Medicine Department, Hospital 4Methotrexate 4Doxorubicin 4cixutumumab 3cabozantinib 3Temozolomide 3Leucovorin 3Filgrastim 3Cyclophosphamide 3Cisplatin 3ulixertinib 2tipifarnib 2temsirolimus 2tazemetostat 2tanespimycin 2selpercatinib 2palbociclib 2olaparib 2merphos 2larotrectinib 2ixabepilone 2ivosidenib 2ensartinib 2dinutuximab 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Osteosarcoma × trastuzumab deruxtecan × Clear all
NCT04616560 2026-05-13

Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma

National Cancer Institute (NCI)

Phase 2 Suspended
77 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡